Effect of piroxicam administration in infertile women undergoing assisted reproductive technologies: A systematic review and meta-analysis

Abstract

Objective

To evaluate piroxicam effect on different pregnancy outcomes among infertile women undergoing assisted reproductive technologies (ART).

Methods

We searched for the available randomized clinical trials (RCTs) in four different databases during January 2021 that compared piroxicam (intervention group) to placebo/no treatment (control group) in infertile women performing ART. We extracted the available data from included studies and pooled them in a meta-analysis model using RevMan software. We pooled the dichotomous data as risk ratios (RR) with the corresponding 95% confidence intervals (CI) using RevMan software. Our outcomes were rates of clinical pregnancy, ongoing pregnancy, miscarriage, and any adverse events.

Results

Seven RCTs met our inclusion criteria with a total number of 1226 patients. Piroxicam was linked to a significant increase in clinical pregnancy rate compared to control group (RR = 1.30, 95% CI [1.09, 1.55], p = .003). However, we did not report any significant difference between both groups in ongoing pregnancy rate (RR = 1.27, 95% CI [0.72, 2.24], p = .41). In addition, the rates of miscarriage and adverse events were not different among both groups.

Conclusions

Piroxicam administration increases the clinical pregnancy rate among infertile women. However, piroxicam does not affect miscarriage and ongoing pregnancy rates.

吡洛昔康在接受辅助生殖技术的不孕女性中的应用效果:一项系统回顾和荟萃分析 摘要

目的:评价吡洛昔康对接受辅助生殖技术不孕女性不同妊娠结局的影响。方法:2021年1月, 我们在四个不同的数据库中搜索了在接受ART的不孕女性中比较吡洛昔康(干预组)与安慰剂/无治疗(对照组)的随机临床试验。我们从纳入的研究中提取可用数据, 并使用RevMan软件将其整合到一个荟萃分析模型中。我们使用RevMan软件将二分类数据合并为风险比和相应的95%置信区间。我们的结果是临床妊娠、持续妊娠、流产和任何不良事件的发生率。结果:7个随机对照试验符合我们的纳入标准, 共有1226名患者。与对照组相比, 吡洛昔康与临床妊娠率显著提高相关(RR = 1.30, 95% CI [1.09, 1.55], p = .003)。然而, 我们没有发现两组之间的持续妊娠率有任何显著差异(RR = 1.27, 95% CI [0.72, 2.24], p = .41)。此外, 两组的流产率和不良事件率也没有差异。结论:吡洛昔康可增加不孕女性的临床妊娠率。但不影响流产和持续妊娠率。

Keywords:

• Piroxicam
• pregnancy
• assisted reproductive technologies
• ART

Disclosure statement

No potential conflict of interest was reported by the author(s).

Sources of financial support for the research

None.